[go: up one dir, main page]

WO2006133398A3 - In vitro activated donor t-cells to promote transplant engraftment - Google Patents

In vitro activated donor t-cells to promote transplant engraftment Download PDF

Info

Publication number
WO2006133398A3
WO2006133398A3 PCT/US2006/022426 US2006022426W WO2006133398A3 WO 2006133398 A3 WO2006133398 A3 WO 2006133398A3 US 2006022426 W US2006022426 W US 2006022426W WO 2006133398 A3 WO2006133398 A3 WO 2006133398A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
activated donor
vitro activated
transplant engraftment
engraftment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/022426
Other languages
French (fr)
Other versions
WO2006133398A2 (en
Inventor
Ronald J Berenson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Life Technologies Corp
Original Assignee
Invitrogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invitrogen Corp filed Critical Invitrogen Corp
Publication of WO2006133398A2 publication Critical patent/WO2006133398A2/en
Publication of WO2006133398A3 publication Critical patent/WO2006133398A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates generally to promoting transplant engraftment, immune reconstitution, and reducing conditioning-related toxicity associated with allotransplantation using allogeneic donor lymphocytes, in particular, activated donor T cells. Further, the present invention relates generally to methods for stimulating and activating cells which can then be used in transplant settings.
PCT/US2006/022426 2005-06-08 2006-06-08 In vitro activated donor t-cells to promote transplant engraftment Ceased WO2006133398A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68863005P 2005-06-08 2005-06-08
US60/688,630 2005-06-08

Publications (2)

Publication Number Publication Date
WO2006133398A2 WO2006133398A2 (en) 2006-12-14
WO2006133398A3 true WO2006133398A3 (en) 2007-04-19

Family

ID=37387249

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/022426 Ceased WO2006133398A2 (en) 2005-06-08 2006-06-08 In vitro activated donor t-cells to promote transplant engraftment

Country Status (1)

Country Link
WO (1) WO2006133398A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9089520B2 (en) * 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
WO2013040371A2 (en) * 2011-09-16 2013-03-21 Baylor College Of Medicine Targeting the tumor microenvironment using manipulated nkt cells
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
CA2912172A1 (en) 2013-06-05 2014-12-11 Bellicum Pharmaceuticals, Inc. Methods for inducing partial apoptosis using caspase polypeptides
ES2904301T3 (en) 2014-11-03 2022-04-04 Academisch Ziekenhuis Leiden H O D N Leids Univ Medisch Centrum Anti-Bob1 T cell receptors and uses thereof
WO2018068022A1 (en) 2016-10-06 2018-04-12 Poseida Therapeutics, Inc. Inducible caspases and methods for use
KR20190142775A (en) 2017-04-19 2019-12-27 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Immune Cells Expressing Engineered Antigen Receptors
CA3072777A1 (en) 2017-09-08 2019-03-14 Poseida Therapeutics, Inc. Compositions and methods for chimeric ligand receptor (clr)-mediated conditional gene expression
WO2019126574A1 (en) 2017-12-20 2019-06-27 Poseida Therapeutics, Inc. Vcar compositions and methods for use
WO2019165121A1 (en) 2018-02-21 2019-08-29 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses therof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1241249A1 (en) * 2001-03-12 2002-09-18 Gerold Schuler CD4+CD25+regulatory T cells from human blood
US20030064067A1 (en) * 2001-10-01 2003-04-03 Kirin Beer Kabushiki Kaisha Method for inducing differentiation and promoting proliferation of regulatory T cell
WO2004003142A2 (en) * 2002-06-28 2004-01-08 Xcyte Therapies, Inc. Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
EP1391210A2 (en) * 2002-08-12 2004-02-25 Gerold Schuler Regulatory medicament comprising CD4+CD25- T cells and Tr1-like regulatory cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1241249A1 (en) * 2001-03-12 2002-09-18 Gerold Schuler CD4+CD25+regulatory T cells from human blood
US20030064067A1 (en) * 2001-10-01 2003-04-03 Kirin Beer Kabushiki Kaisha Method for inducing differentiation and promoting proliferation of regulatory T cell
WO2004003142A2 (en) * 2002-06-28 2004-01-08 Xcyte Therapies, Inc. Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
EP1391210A2 (en) * 2002-08-12 2004-02-25 Gerold Schuler Regulatory medicament comprising CD4+CD25- T cells and Tr1-like regulatory cells

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Xcyte Therapies Presents Clinical Results From Clinical Trials In Chronic Lymphocytic Leukemia And Multiple Myeloma At The American Society of Hematology (ASH)", BIOSPACE BEAT, 10 December 2003 (2003-12-10), XP002408867, Retrieved from the Internet <URL:http://www.biospace.com/news_story.aspx?StoryID=14618620&full=1> [retrieved on 20061116] *
DROBYSKI W R ET AL: "Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 SEP 1998, vol. 161, no. 5, 1 September 1998 (1998-09-01), pages 2610 - 2619, XP002407885, ISSN: 0022-1767 *
GRIBBEN, J. G. ET AL: "A phase II study of Xcellerated T Cells in patients with relapsed or refractory indolent non-Hodgkin's lymphoma (NHL)", 2005 ASCO ANNUAL MEETING, ABSTRACT NO: 2510, 13 May 2005 (2005-05-13) - 17 May 2005 (2005-05-17), XP002408871, Retrieved from the Internet <URL:http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=34&abstractID=31510> [retrieved on 20061116] *
JONES S C ET AL: "Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD4<+>25<+> T cells to allow an effective graft-versus-leukemia response", BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, KLUGE CARDEN JENNINGS PUBLISHING, CHARLOTTESVILLE, VA, US, vol. 9, no. 4, April 2003 (2003-04-01), pages 243 - 256, XP004689219, ISSN: 1083-8791 *
KALAMASZ D ET AL: "OPTIMIZATION OF HUMAN T-CELL EXPANSION EX VIVO USING MAGNETIC BEADS CONJUGATED WITH ANTI-CD3 AND ANTI-CD28 ANTIBODIES", JOURNAL OF IMMUNOTHERAPY, RAVEN PRESS, NEW YORK, NY, US, vol. 27, no. 5, September 2004 (2004-09-01), pages 405 - 417, XP009067003, ISSN: 1053-8550 *
KIPPS T. J. ET AL: "A Phase I/II Study of Xcellerated T CellsTM in Patients with Chronic Lymphocytic Leukemia", 2005 ASCO ANNUAL MEETING, ABSTRACT NO: 2511, 13 May 2005 (2005-05-13) - 17 May 2005 (2005-05-17), XP002408870, Retrieved from the Internet <URL:http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=34&abstractID=31522> [retrieved on 20061116] *
MARKTEL SARAH ET AL: "Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation.", BLOOD. 15 FEB 2003, vol. 101, no. 4, 15 February 2003 (2003-02-15), pages 1290 - 1298, XP002407888, ISSN: 0006-4971 *
NAPOLES PHYLLIS E. ET AL: "MESENCHYMAL STEM CELLS CAN REDUCE CONDITIONING REQUIREMENTS FOR ALLOGENEIC ENGRAFTMENT.(Abstract# 1141 Poster Board #-Session: P71-III)", AMERICAN JOURNAL OF TRANSPLANTATION,(AMERICAN TRANSPLANT CONGRESS 2004), vol. 4, no. s8, March 2004 (2004-03-01), pages 470, XP002408868 *
RAPOPORT A P ET AL: "Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells.", BONE MARROW TRANSPLANTATION. JAN 2004, vol. 33, no. 1, January 2004 (2004-01-01), pages 53 - 60, XP002407887, ISSN: 0268-3369 *
RETTIG MICHAEL P ET AL: "Kinetics of in vivo elimination of suicide gene-expressing T cells affects engraftment, graft-versus-host disease, and graft-versus-leukemia after allogeneic bone marrow transplantation.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 SEP 2004, vol. 173, no. 6, 15 September 2004 (2004-09-15), pages 3620 - 3630, XP002407889, ISSN: 0022-1767 *
TAYLOR PATRICIA A ET AL: "L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection.", BLOOD. 1 DEC 2004, vol. 104, no. 12, 1 December 2004 (2004-12-01), pages 3804 - 3812, XP002407884, ISSN: 0006-4971 *
TAYLOR PATRICIA A ET AL: "The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality.", BLOOD. 15 MAY 2002, vol. 99, no. 10, 15 May 2002 (2002-05-15), pages 3493 - 3499, XP002407886, ISSN: 0006-4971 *
THORNTON ANGELA M ET AL: "Activation requirements for the induction of CD4+CD25+ T cell suppressor function.", EUROPEAN JOURNAL OF IMMUNOLOGY. FEB 2004, vol. 34, no. 2, February 2004 (2004-02-01), pages 366 - 376, XP002407890, ISSN: 0014-2980 *
VIJ R. ET AL: "A randomized phase II study of Xcellerated T Cells with or without prior fludarabine therapy in patients with multiple myeloma (MM)", 2005 ASCO ANNUAL MEETING, ABSTRACT NO: 2582, 13 May 2005 (2005-05-13) - 17 May 2005 (2005-05-17), XP002408869, Retrieved from the Internet <URL:http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=34&abstractID=31547> [retrieved on 20061116] *

Also Published As

Publication number Publication date
WO2006133398A2 (en) 2006-12-14

Similar Documents

Publication Publication Date Title
WO2008051568A3 (en) Methods and compositions for treatment of bone defects with placental cell populations
WO2008036374A3 (en) Allogeneic stem cell transplants in non-conditioned recipients
EP2727998A3 (en) Methods for purifying pancreatic endoderm cells derived from human embryonic stem cells
WO2009086471A3 (en) Synergistic antiparasitic compositions and screening methods
WO2007095594A3 (en) Methods and compositions for enhancing engraftment of hematopoietic stem cells
WO2009002456A3 (en) Methods and compositions relating to progenitor cells
WO2012052823A3 (en) Passenger seating assemblies and aspects thereof
EP2669366A3 (en) Pluripotent cells
WO2011082038A3 (en) Improved reprogramming compositions
MX2009013706A (en) Multipotent/pluripotent cells and methods.
WO2006020891A3 (en) Chemokine combinations to mobilize progenitor/stem cells
WO2012092420A3 (en) Methods for cryopreserving and encapsulating cells
WO2007097993A3 (en) Media conditioned by human embryonic stem cells or other progenitor cells and uses therefor
WO2007149861A3 (en) Soft tissue repair and regeneration using stem cell products
WO2008006895A3 (en) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta t cell activators
EP2465922A3 (en) Mesenchymal stem cells expressing TNF-alpha receptor
IL189555A0 (en) Compositions of cells enriched for combinations of various stem and progenitor cell populations, methods of use thereof and methods of private banking thereof
MX339068B (en) Methods and compositions for treatment of bone defects with placental cell populations.
CA2801009C (en) Native wharton&#39;s jelly stem cells and their purification
WO2012088157A3 (en) Glp-1 receptor agonists for islet cell transplantation
EP2048227A3 (en) Methods for proliferating stem cells
WO2006133398A3 (en) In vitro activated donor t-cells to promote transplant engraftment
WO2006047743A8 (en) Swine multipotent adult progenitor cells
EP2444483A3 (en) Materials and methods relating to cell based therapies
WO2005108428A3 (en) Cd40 splice variants and their uses

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06784686

Country of ref document: EP

Kind code of ref document: A2